drugset / Trial / NCT00422123
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Timeline
- Start
- 2007-01
- Primary completion
- —
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quetiapine | Small molecule | 400 mg | — |
| Subject | Quetiapine | Small molecule | 800 mg | — |